This Article Full Text Full Text (PDF) Related Article Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Drapkin, R. Articles by Skates, S. PubMed PubMed Citation Articles by Drapkin, R. Articles by Skates, S. Related Collections Key Article

Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy?

Authors' Affiliations: ¹ Department of Medical Oncology, Dana-Farber Cancer Institute; ² Department of Pathology, Brigham and Women's Hospital; ³ Harvard Medical School; and ⁴ Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts

Requests for reprints: Ronny Drapkin, Dana-Farber Cancer Institute, JFB 215D, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4380; Fax: 617-582-8761; E-mail: ronny_drapkin{at}dfci.harvard.edu.

Abstract

Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.

Key Article

Cleaved Forms of the Urokinase Plasminogen Activator Receptor in Plasma Have Diagnostic Potential and Predict Postoperative Survival in Patients with Ovarian Cancer

Emir Henic, Christer Borgfeldt, Ib Jarle Christensen, Bertil Casslén, and Gunilla Høyer-Hansen
Clin. Cancer Res. 2008 14: 5785-5793. [Abstract] [Full Text] [PDF]